• Nadia Soliman, Simon Haroutounian, Andrea G Hohmann, Elliot Krane, Jing Liao, Malcolm Macleod, Daniel Segelcke, Christopher Sena, James Thomas, Jan Vollert, Kimberley Wever, Harutyun Alaverdyan, Ahmed Barakat, Tyler Barthlow, BozerAmber L HarrisALHDepartment of Psychological Sciences, Tarleton State University, Stephenville, TX, United States., Alexander Davidson, Marta Diaz-delCastillo, Antonina Dolgorukova, Mehnaz I Ferdousi, Catherine Healy, Simon Hong, Mary Hopkins, Arul James, Hayley B Leake, Nathalie M Malewicz, Michael Mansfield, Amelia K Mardon, Darragh Mattimoe, Daniel P McLoone, Gith Noes-Holt, Esther M Pogatzki-Zahn, Emer Power, Bruno Pradier, Eleny Romanos-Sirakis, Astra Segelcke, Rafael Vinagre, Julio A Yanes, Jingwen Zhang, Xue Ying Zhang, David P Finn, and RiceAndrew S CASCPain Research, Department of Surgery and Cancer, Imperial College London, London, United Kingdom..
• Pain Research, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
• Pain. 2021 Jul 1; 162 (Suppl 1): S26S44S26-S44.

AbstractWe report a systematic review and meta-analysis of studies that assessed the antinociceptive efficacy of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators on pain-associated behavioural outcomes in animal models of pathological or injury-related persistent pain. In April 2019, we systematically searched 3 online databases and used crowd science and machine learning to identify studies for inclusion. We calculated a standardised mean difference effect size for each comparison and performed a random-effects meta-analysis. We assessed the impact of study design characteristics and reporting of mitigations to reduce the risk of bias. We meta-analysed 374 studies in which 171 interventions were assessed for antinociceptive efficacy in rodent models of pathological or injury-related pain. Most experiments were conducted in male animals (86%). Antinociceptive efficacy was most frequently measured by attenuation of hypersensitivity to evoked limb withdrawal. Selective cannabinoid type 1, cannabinoid type 2, nonselective cannabinoid receptor agonists (including delta-9-tetrahydrocannabinol) and peroxisome proliferator-activated receptor-alpha agonists (predominantly palmitoylethanolamide) significantly attenuated pain-associated behaviours in a broad range of inflammatory and neuropathic pain models. Fatty acid amide hydrolase inhibitors, monoacylglycerol lipase inhibitors, and cannabidiol significantly attenuated pain-associated behaviours in neuropathic pain models but yielded mixed results in inflammatory pain models. The reporting of criteria to reduce the risk of bias was low; therefore, the studies have an unclear risk of bias. The value of future studies could be enhanced by improving the reporting of methodological criteria, the clinical relevance of the models, and behavioural assessments. Notwithstanding, the evidence supports the hypothesis of cannabinoid-induced analgesia.Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.

12 keywords...

hide…